Michael Spandorfer, MD
Pulmonary Disease · Charleston, SCNPI 1134122112
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.6% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2022 at $6,363 and has fallen 73.9% since, to $1,662 in 2025.
Across 219 payments — averaging $52.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Insmed, Inc.$684
- United Therapeutics Corporation$620
- GSK$576
- Boehringer Ingelheim$345
- AstraZeneca$299
- plus $2K from 27 others
What the payments were for
- Travel & lodging$2,98926%
- Food & beverage$5,54648%
- Education$3,03926%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 30 | $7,136 |
| Insmed, Inc. | 23 | $684 |
| United Therapeutics Corporation | 21 | $620 |
| GSK | 30 | $576 |
| Boehringer Ingelheim | 13 | $345 |
| AstraZeneca | 14 | $299 |
| Sanofi | 8 | $269 |
| ANI Pharmaceuticals, Inc. | 12 | $210 |
| Merck | 8 | $167 |
| Verona Pharma, Inc. | 7 | $167 |
| Amgen | 6 | $142 |
| Philips North America LLC | 7 | $142 |
| Mallinckrodt Hospital Products Inc. | 5 | $141 |
| Sunovion Pharmaceuticals Inc. | 7 | $95 |
| Actelion Pharmaceuticals US, Inc. | 3 | $80 |
| Mylan Specialty L.p. | 3 | $78 |
| Novartis | 4 | $71 |
| Regeneron Healthcare Solutions, Inc. | 2 | $66 |
| Johnson & Johnson | 1 | $29 |
| Resmed Corp | 1 | $27 |
| Astellas Pharma US Inc | 1 | $25 |
| Gilead | 1 | $23 |
| Baxter Healthcare | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Harmony Biosciences LLC | 1 | $19 |
| Pfizer | 1 | $19 |
| Vapotherm Inc | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Inogen, Inc. | 2 | $16 |
| Electromed, Inc. | 1 | $15 |
| Veran Medical Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,758
- ION$3,000
How this compares
$11,588 in reported general payments places this provider in the 75th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 423 | $482,999 |
| OfevNintedanib Esylate | 37 | $407,995 |
| XolairOmalizumab | 56 | $154,111 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 110 | $115,672 |
| NucalaMepolizumab | 15 | $81,508 |
| Breo ElliptaFluticasone/Vilanterol | 99 | $78,885 |
| Dupixent PenDupilumab | 12 | $66,888 |
| Spiriva RespimatTiotropium Bromide | 48 | $55,320 |
| SymbicortBudesonide/Formoterol Fumarate | 108 | $47,560 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $31,973 |
| Advair HfaFluticasone Propion/Salmeterol | 66 | $31,837 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $29,193 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 679 | $26,055 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 36 | $21,756 |
| Spiriva HandihalerTiotropium Bromide | 28 | $19,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $576 | $684,564581 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $345 | $517,043167 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $299 | $166,217231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Charleston
- Patrick FlumeCharleston$418K
- Gerard SilvestriCharleston$254K
- Denise Gabrielle SeseCharleston$51K
- Timothy WhelanCharleston$41K
- Marc JudsonCharleston$28K
- John HugginsCharleston$18K
- John CoxCharleston$16K
- Adam FoxCharleston$13K
- Rachana KrishnaCharleston$9K
- Abhijit RavalAnderson$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.